101 related articles for article (PubMed ID: 23635918)
1. New blood test can detect genes that drive cancer and help to determine best treatment.
Kmietowicz Z
BMJ; 2013 May; 346():f2825. PubMed ID: 23635918
[No Abstract] [Full Text] [Related]
2. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
[No Abstract] [Full Text] [Related]
3. HER2 testing: the patent "genee" is out of the bottle.
Goldman B
CMAJ; 2007 May; 176(10):1443-4. PubMed ID: 17485697
[No Abstract] [Full Text] [Related]
4. [Herceptin].
Morginstin T; Shani S; Shemer J
Harefuah; 2000 Mar; 138(6):459-64. PubMed ID: 10883160
[No Abstract] [Full Text] [Related]
5. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
6. Trastuzumab in CNS progressive metastatic breast cancer.
Tosoni A; Franceschi E; Esposti RD; Brandes AA
Future Oncol; 2007 Aug; 3(4):367-9. PubMed ID: 17661709
[No Abstract] [Full Text] [Related]
7. Adjuvant trastuzumab for breast cancer: assessing HER2/neu status incurs more costs for treatment.
Kell MR; Power CP
BMJ; 2005 Nov; 331(7526):1202. PubMed ID: 16293849
[No Abstract] [Full Text] [Related]
8. [Breast cancer].
Tokuda Y; Saito Y; Suzuki Y; Ohta M; Tajima T
Nihon Rinsho; 2002 Mar; 60(3):563-9. PubMed ID: 11904974
[TBL] [Abstract][Full Text] [Related]
9. Current perspective - trastuzumab.
Hall PS; Cameron DA
Eur J Cancer; 2009 Jan; 45(1):12-8. PubMed ID: 19042123
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
11. Oncogramme responses of breast tumour cells treated with herceptin correlate with HER2/C-ERB B2 pathological status.
Giraud S; Bounaix Morand du Puch C; Fermeaux V; Guillaudeau A; Lautrette C
Anticancer Res; 2012 Apr; 32(4):1323-5. PubMed ID: 22493365
[TBL] [Abstract][Full Text] [Related]
12. [ERBB2/HER2: from molecular to clinical oncology].
Khanson KP; Imianitov EN
Vopr Onkol; 2002; 48(2):137-45. PubMed ID: 12227060
[No Abstract] [Full Text] [Related]
13. What is the ideal HER2 test for Herceptin therapy?
Jpn J Clin Oncol; 2000 Apr; 30(4):208-9, 211. PubMed ID: 10830993
[No Abstract] [Full Text] [Related]
14. Role of erbB2 in breast cancer chemosensitivity.
Yu D; Hung MC
Bioessays; 2000 Jul; 22(7):673-80. PubMed ID: 10878580
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 testing: where are we?
De P; Smith BR; Leyland-Jones B
J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
[No Abstract] [Full Text] [Related]
16. [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
Bult P; Tjan-Heijnen VC; van Krieken H
Ned Tijdschr Geneeskd; 2006 Jul; 150(26):1481; author reply 1481-3. PubMed ID: 16875274
[No Abstract] [Full Text] [Related]
17. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab emtansine for advanced HER2-positive breast cancer and beyond: genome landscape-based targets.
Cho WC; Roukos DH
Expert Rev Anticancer Ther; 2013 Jan; 13(1):5-8. PubMed ID: 23259420
[No Abstract] [Full Text] [Related]
19. [Herceptin (trastuzumab). A new exciting therapeutic principle in breast cancer].
Holm-Hansen SV; Kamby C; Dombernowsky P
Ugeskr Laeger; 2000 Jan; 162(2):189-90. PubMed ID: 10647320
[No Abstract] [Full Text] [Related]
20. Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside.
Hanna W; Kahn HJ; Trudeau M
Mod Pathol; 1999 Aug; 12(8):827-34. PubMed ID: 10463486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
